<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity</title>
    <meta name="description" content="2021 Jan 14;7(1):3.; Sci Rep 15, 23495 (2025).; 2014 Oct 21;121(5):664–672." />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity</h1>
<div class="muted">2025-09-08 15:00:00+00:00</div>
<hr />
<div class="list"><ul>
  <li>2021 Jan 14;7(1):3.</li><li>Sci Rep 15, 23495 (2025).</li><li>2014 Oct 21;121(5):664–672.</li><li>Food and Drug Administration (“FDA”) for the treatment of patients with small cell lung cancer in 2025.</li><li>The 5-year survival rate for patients with extensive-stage SCLC is only 5%, emphasizing the need for new treatment options that extend progression-free survival.2, 3 About pumitamig (also known as BNT327 or BMS986545) Pu</li><li>About Small Cell Lung Cancer Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases, with an estimated 250,000 new cases globally per year.1 It is the most aggressive type of lung cancer often spreading</li><li>doi: 10.1038/s41572-020-00235-0.</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=First+Disclosure+of+Global+Interim+Phase+2+Data+for+BioNTech+and+Bristol+Myers+Squibb+PD-L1xVEGF-A+Bispecific+Antibody+Pumitamig+%28BNT327%2FBMS986545%29+in+Patients+with+Extensive-Stage+Small+Cell+Lung+Cancer+Shows+Encouraging+Antitumor+Activity%0A%E2%80%A2+2021+Jan+14%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Ffirst-disclosure-of-global-interim-phase-2-data-for-biontech-and-bristol-myers-s%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>